K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

Serum antibodies to Neisseria meningitidis group B (MenB) polysaccharide are reported not to elicit bacteriolysis in the presence of human complement. To reexamine this question, we evaluated the ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

Activation of the complement system through the alternative pathway is necessary for the development of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in animal models C5a has ...

argenx and Broteio Pharma have partnered to develop a therapeutic antibody against a complement cascade target through to preclinical proof of concept. The firms say the antibody has the potential to ...

THE report with Weller, in 1962, of microcephaly in 14 of 17 infants with generalized cytomegalic inclusion disease established the association of this Central-nervous-system defect with intrauterine ...

CLEVELAND, Sept. 25, 2013 /PRNewswire-USNewswire/ -- Today NovelMed Therapeutics announced preclinical study results for its lead compound in two models of AMD, a major cause of blindness affecting ...

The factors controlling lysis of gram-negative bacteria by complement are being investigated systematically. The first question was how smooth Salmonella minnesota, which has on its surface ...

PREVIOUS reports from this Laboratory 1–3 have shown that human growth hormone (HGH) and sheep interstitial cell stimulating hormone (ICSH) produce, in rabbits, precipitin antibodies that are specific ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal ...